Haywood Cochrane

Jan 09, 2017

Acuamark Diagnostics announced Haywood Cochrane has joined its board of directors. He will transition from his current position as a member of the firm's advisory board. Cochrane is currently a director at Corium and vice chair of the board at the University of North Carolina, Chapel Hill. Previously, he was CEO of CHD Meridian and was president and CEO of Allied Clinical Labs. 

More Like This

Dec 18, 2018

Jessica Hassel, Aurélien Marabelle

Protagen has appointed Jessica Hassel and Aurélien Marabelle to the firm's scientific advisory board. The members will support the company in developing and implementing its immuno-profiling technology. Hassel is currently the head of dermato-oncology at Germany's National Center for Tumor Disease. She has worked at the German Cancer Research Center Heidelberg, with a focus on translational oncology. Marabelle is currently the clinical director of the Cancer Immunotherapy Program at Gustave Roussy Cancer Center in Villejuif, France. He works as a senior medical oncologist and an investigator in the center's drug development department. 

Dec 17, 2018

Amy Abernethy

Amy Abernethy, current chief medical officer, CSO, and senior VP of oncology at Flatiron Health will join the US Food and Drug Administration as principal deputy commissioner, second to the agency's commissioner Scott Gottlieb. She is slated to join the agency in early 2019, pending ethics clearances, and will replace Rachel Sherman, who is retiring as the FDA's current principal deputy commissioner. Patrizia Cavazzoni, who is deputy director for operations at the FDA's drug center, will step in as interim principal deputy commissioner till Abernethy joins.

Abernethy became an executive at the cancer focused health technology firm Flatiron more than four years ago. She currently serves as a member of the board for CareDx, and will step down from that post effective Jan. 31, 2019. She has served as a director on the company's board since July 2018 as chairman of the scientific committee. Abernethy has also worked at Athenahealth and directed the Duke Center for Learning Health Care. In an internal email about Abernethy's hire, the FDA highlighted that she is an internationally recognized expert in clinical trials, cancer outcomes research, health policy, patient-reported outcomes, and patient-centered care, and has authored more than 400 peer-reviewed articles.

The non-profit advocacy organization Personalized Medicine Coalition, where Abernethy serves as a board member, noted in a statement that the agency's decision to hire her reflects its increasing focus on personalized medicine. While Abernethy was at Flatiron, the company struck up a research alliance with the FDA to explore how real-world data, derived from sources outside of the traditional clinical trial setting, could be used to gather evidence on the safety and efficacy of cancer treatments.

Dec 17, 2018

Richard Marsh, Benjamin Jackson

Richard Marsh, executive VP of Myriad Genetics, as well as its general counsel and secretary, will retire from the company effective July 1, 2019.  After serving as Myriad's general counsel for more than 16 years, Marsh has acceped the job of mission president for the Church of Jesus Christ of Latter-day Saints for the next three years.

Benjamin Jackson, currently Myriad's VP, assistant general counsel, and assistant secretary, will succeed Marsh. Jackson has been with the company since 2006 and has held positions dealing with commercial operations and intellectual property issues.

Dec 14, 2018

Lawrence Weiss

NeoGenomics announced the appointment of Lawrence Weiss as chief scientific officer. Weiss has served as medical director and laboratory director for NeoGenomics since joining the company as part of the Clarient Diagnostic Services acquisition of 2015. As chief scientific officer, he is responsible for driving NeoGenomics scientific innovation initiatives and advancing the company's reputation in the oncology diagnostics community. Prior to joining NeoGenomics, Weiss served as laboratory director for Clarient and as chairman of the department of pathology and director of laboratories for the City of Hope National Medical Center. 

Dec 13, 2018

Peter Johnson, Richard Roope, Nora Pashayan, Ola Winqvist

Oncimmune appointed a new scientific board this week comprising Peter Johnson; Richard Roope; Nora Pashayan; and Ola Winqvist. Johnson is a professor of medical oncology in Southampton, CRUK's chief clinician, and director of the Francis Crick Institute Cancer Research Network. 

Roope is a general practitioner and UK clinical lead for cancer at the Royal College of General Practitioners. He is a senior clinical advisor at CRUK and a member of the National Cancer Advisor Group. Pashayan is a clinical reader in applied health research at University College London and a member of the Breast Cancer Now advisory board, and Winqvist is a professor of cellular immunotherapy at the Karolinska Institute and senior consultant in clinical immunology at the Karolinska University Hospital. 

Dec 12, 2018

Melissa Lueke, Eric Rasmussen, Bryan Baldasare

Executive VP and CFO at Meridian Bioscience, Melissa Lueke, will retire from her position effective January 1, 2019. Lueke, who has been at Meridian for 20 years, will remain with the firm in a paid financial consulting role with a renewable contract of three years.

Meridian also promoted Eric Rasmussen from his role as EVP of Corporate Development to the position of EVP, CFO, and Principal Financial Officer, also effective January 1, 2019. Rasmussen was hired by Meridian in June of 2018, and previously served in corporate development and financial leadership roles at Lear Corporation, an automotive seating and electrical systems supplier. Rasmussen has also served on the advisory board of Exploragen, a DNA lifestyle company.

Meridian has also promoted Bryan Baldasare to the role of Chief Accounting Office. Baldasare has been with Meridian since 2000, and most recently served as Senior VP, Corporate Controller and Treasurer.

Dec 11, 2018

Catherine Friedman, Alex Aravanis

Grail has appointed Catherine Friedman as chair of the firm's board of directors. Friedman succeeds Bill Rastetter, who will continue to serve as a director of the firm's board. Friedman joined the board in July 2017. She has also held numerous executive positions during her investment banking career with Morgan Stanley, including as managing director and head of West Coast healthcare, and co-head of the biotechnology practice. Friedman is also a board member at Altaba, Radius Health, and Lyell Immunopharma.

Grail has also appointed Alex Aravanis as CSO and head of R&D. Aravanis is a cofounder of Grail. Prior to being CSO, Aravanis served as VP of research and development. He previously served as senior director of R&D for Illumina. In addition, Aravanis served as VP of development and CSO of Sapphire Energy and was a cofounder and VP of engineering of Pria Diagnostics.

Dec 11, 2018

Hans Clevers

The board of directors of Roche Holding has proposed Hans Clevers as a new board member. He is scheduled to be elected to the board at the company's annual general meeting on March 5, 2019. Clevers is a professor of molecular genetics at the University Medical Center Utrecht in the Netherlands.

Dec 10, 2018

Daniel O'Day, William Anderson

Daniel O'Day will leave his post as CEO and corporate executive committee member of Roche Pharmaceuticals at the end of December to become CEO and board chairman of Gilead Sciences, effective March 1, 2019.

In the interim period, he will provide support to Roche to ensure a smooth transition to his successor, William Anderson, who will become CEO of Roche Pharmaceuticals effective Jan. 1, 2019. Anderson currently serves as CEO of Roche-owned Genentech, which he joined in 2006. In previous roles, he led Genentech's immunology business unit, headed oncology sales and marketing, and led global product strategy.

Dec 10, 2018

Prahlad Singh

Prahlad Singh has been appointed president and chief operating officer of PerkinElmer, effective Jan. 1, 2019. Singh will be responsible for the Discovery and analytical solutions and the diagnostics operating divisions. He joined PerkinElmer in 2014 as president of the diagnostics business, was elected as an officer in 2016 and executive vice president in 2016. Prior to joining the firm, Singh served as general manager of GE Healthcare's women's health business. He has also held senior executive level positions in strategy, business development, and M&A at GE and at Philips Healthcare.


Dec 10, 2018

Bradley Cole

Castle Biosciences announced Bradley Cole has been appointed to its board. Cole is the CFO of Genomic Health and has more than 30 years of experience in finance and operations in the diagnostics and life sciences industries. He also has served as COO of Genomic Health. Prior to joining the firm, he was VP of finance and business development for the endovascular solutions group at Guiidant, and was VP and GM of vascular surgery business unit of Guidant. 

Nov 30, 2018

Joan Martin

Joan Martin has joined Ortho Clinical Diagnostics as vice president of Europe, the Middle East, and Africa. He will be in charge of the company's commercial operations in the region. Martin was previously executive vice president and head of Europe, the Middle East, and Africa at Accelerate Diagnostics. 

Nov 26, 2018

Reginald Seeto

CareDx has appointed Reginald Seeto to the newly created role of president and chief business officer. Seeto has 20 years of experience in commercial operations, corporate development, and strategy, most recently serving as chief operating officer at Ardelyx. He has also worked at AstraZeneca/Medimmune and was a member of the MedImmune executive team. His responsibilities there included leading corporate development and strategy, global strategic marketing, and portfolio management for all therapeutic areas, as well as a country leadership role at AstraZeneca in Thailand. Before AstraZeneca, Seeto held positions at Organon Biosciences and at McKinsey.

Nov 19, 2018

Jason Ryan

Jason Ryan will leave his post as CFO of Foundation Medicine to become chief operating and financial officer at Magenta Therapeutics, effective January 1 of 2019. Prior to joining Foundation Medicine, he held management positions for Taligen Therapeutics, Codon Devices, and Genomics Collaborative. Ryan holds a BS in economics from Bates College and an MBA from Babson College. Foundation Medicine has not announced a successor for Ryan yet.

Nov 13, 2018

Steve Ziganti, Patrik Jeanmonod, Jack Ball, Allen Poirson

Cytek Biosciences announced Steve Ziganti has joined the firm as vice president of worlwide sales and Patrik Jeanmonod has been hired as the company's chief financial officer. 

Additionally, Jack Ball and Allen Poirson have joined Cytek's board of directors. 

Ziganti was previously VP of sales and service at BD Biosciences before retiring from that firm. Jeanmonod has previously held executive positions in finance at Covance, Bridge Pharmaceuticals, and Synteract. He is currently a board member at Seal Biosciences. 

Ball formerly was the CEO of Amnis and CCO of Accuri Cytomers and Molecular Probes. Poirson is a partner at Mighty Capital and previously was CEO of Sony Biotechnology.